['hypercholesterolemia']
['etc-1002', 'placebo', 'statin therapy']

        Inclusion Criteria:

          -  Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL

          -  Fasting mean TG level ≤400 mg/dL

          -  Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20
             mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or
             pravastatin (10, 20 or 40 mg daily)

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease within 12 months of screening

          -  Current muscle-related symptoms that may be due to ongoing statin therapy or a history
             of certain lab abnormalities that occurred during statin therapy and resolved when
             statin therapy was discontinued

          -  Type 1 diabetes or uncontrolled type 2 diabetes

          -  Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening

          -  History of chronic musculoskeletal symptoms such as fibromyalgia

          -  Uncontrolled hypothyroidism

          -  Liver disease or dysfunction

          -  Renal dysfunction or nephritic syndrome

          -  Gastrointestinal conditions or procedures or surgeries

          -  Hematologic or coagulation disorders or low hemoglobin levels

          -  HIV or AIDS

          -  History of malignancy

          -  History of drug or alcohol abuse within 2 years

          -  Use of experimental or investigational drugs within 30 days of screening

          -  Use of ETC-1002 in a previous clinical study
      